CAE signs contract with PYURE to manufacture air sanitizers in the fight against COVID-19
Under the agreement with PYURE, CAE expects to produce 55,000 units during the first year.
Research & Development
MONTREAL — CAE announced on Feb. 2 that it has signed a contract with The PYURE Company to assemble air sanitizers using PYURE’s technology that has demonstrated through an independent U.S. certified scientific lab to significantly destroy the COVID-19 virus in the air and on surfaces.
CAE will work with PYURE to develop the next generation of products using PYURE’s technology and plans to retrofit its facilities and simulators with the technology.
“The contract with PYURE will allow us to maintain manufacturing jobs in Montreal while continuing to play a role in the fight against the pandemic,” said Marc Parent, President and CEO of CAE. “We obtained this contract mainly because of the expertise we have gained developing the CAE Air1 ventilators as well as the ISO 13485:2016 certification for medical device design, manufacturing and distribution obtained last month.”
“We continuously find innovative ways to provide solutions to make the world a safer place. CAE has been an innovation powerhouse for more than 70 years, with world-class engineering, intellectual property, supply chain and manufacturing capabilities,” Parent added.
Under the agreement with PYURE, CAE expects to produce 55,000 units during the first year. PYURE air sanitizers are used in hospitals, doctors’ and dentists’ offices, senior care centres, high-technology companies and schools in the United States.
“Unlike conventional air purifiers, our technology does not limit purification to the air that is pulled through the unit,” said PYURE Chief Executive Officer Jean-François Huc. “PYURE’s innovative, patented technology replicates the way sunlight sanitizes the outdoor environment by safely generating and diffusing hydroxyls and organic oxidants indoors.
All PYURE air sanitization products and solutions are powered by the same hydroxyl and organic oxidant generating technology. PYURE’s MDU/Rx™ product is registered with the FDA as a class II medical device.